Zero Defects: JOINN (Suzhou) Passes Japan’s PMDA GLP On-Site Inspection

This year, JOINN (Suzhou) has passed GLP inspections by Korea's MFDS, the US FDA, China's NMPA and, most recently, Japan's PMDA, the last of which it passed with zero defects. Its quality management system and data integrity have stood up to rigorous scrutiny from regulators at home and abroad. Building on this solid foundation of compliance, JOINN will continue to support global registration submissions for innovative drugs.

Four GLP inspections passed at Suzhou JOINN in 2026:
🇰🇷 MFDS (Korea): early 2026
🇺🇸 US FDA: May, unannounced
🇨🇳 NMPA (China): June, certificate renewal
🇯🇵 PMDA (Japan): September

For sponsors, this means one non-clinical safety data package that can support filings in China, the US, Korea, Japan and beyond. To date, JOINN has supported 99 projects in entering global markets.

Thank you to our team for being inspection-ready every day, and to our partners for their continued trust.


Prev: Good News! JOINN Medical Testing Earns CAP Accreditation for Immunohistochemistry Testing